Our Services
Medical Information
Helpful Resources
Published on: 7/21/2026
GLP-1 medications, such as Ozempic and Wegovy, can cause muscle loss alongside fat reduction, potentially impacting strength, mobility, and long-term physical function. However, this risk can be minimized through resistance training, adequate protein intake (typically 1.2–1.6g per kg of body weight), and regular monitoring of body composition rather than just weight.
If you're taking a GLP-1 drug—or considering one—and notice changes in strength, energy, or mobility, it's important to understand whether your symptoms are typical side effects or signs of something that needs medical attention. A free, instant, online symptom check can help you clarify what's happening in your body, identify possible causes, and guide your next steps with confidence. It takes just a few minutes and gives you personalized insights you can bring to your doctor.
Reviewed for medical accuracy: 07/20/2026
GLP-1 drugs, used for diabetes and weight management, can sometimes cause a decrease in muscle mass. This is important because muscles help us move and do everyday activities. If you're experiencing unexpected changes in your body while taking these medications, consider using a free symptom checker to better understand what you're experiencing.
Effects on Muscle Mass:
Strategies to Minimize Muscle Loss:
Considerations for Older Adults:
Overall, while GLP-1 drugs can be helpful, it is important to focus on maintaining muscle health through lifestyle choices and regular check-ups with healthcare providers.
(References)
Neeland IJ, Linge J, & Birkenfeld AL. (2024). Changes in lean body mass with glucagon-like peptide-1- .... Diabetes, obesity & metabolism, 38937282.
Mechanick JI, Butsch WS, Christensen SM, Hamdy O, Li Z, Prado CM, & Heymsfield SB. (2025). Strategies for minimizing muscle loss during use of incretin .... Obesity reviews : an official journal of the International Association for the Study of Obesity, 39295512.
Abbatecola AM, Olivieri F, Corsonello A, Strollo F, Fumagalli A, & Lattanzio F. (2012). Frailty and safety: the example of diabetes. Drug safety, 23446787.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.